Navigation Links
Luminex Corporation Reports Second Quarter 2011 Results

AUSTIN, Texas, Aug. 8, 2011 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced financial results for the second quarter ended June 30, 2011.  Financial and operating highlights include the following:


  • Consolidated second quarter revenue was $47.6 million, a 43% increase over the second quarter of 2010
  • Second quarter 2011 consumable sales of $18.4 million, a 90% increase over the second quarter of 2010
  • Second quarter 2011 shipments of 248 multiplexing analyzers that included 62 MAGPIX® systems, resulting in cumulative life-to-date multiplexing analyzer shipments of 8,145, up 13% from a year ago
  • Consolidated gross profit margin was 71% for the second quarter of 2011
  • Operating income for the second quarter of 2011 was $8.8 million compared with operating income of $2.3 million for the same period last year
  • Received CE marking for the 15-pathogen xTAG® Gastrointestinal Pathogen Panel (GPP)
  • Signed a global sales and distribution agreement with Life Technologies™ Corporation (NASDAQ: LIFE) for our MAGPIX multiplexing instrument for the research market
  • Completed the acquisition of privately-held EraGen® Biosciences, Inc., an innovator in molecular diagnostic testing technologies for infectious disease and genetic applications
  • Received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the xTAG Respiratory Viral Panel FAST (RVP FAST) in early July

  • "Luminex delivered another strong performance in the second quarter of 2011," said Patrick J. Balthrop, president and chief executive officer of Luminex.  "Our consumable, royalty revenue and assay categories each demonstrated excellent growth over the prior year period. Consumable revenue reached an all-time record in the second quarter, royalty revenue grew 52% while our assay group, led by our Cystic Fibrosis and Respiratory Viral Panel franchises, generated solid 24% growth. In addition, we continue to expand our installed base at a healthy rate and look forward to ramping up our MAGPIX placements." 

    "During the quarter we achieved several significant milestones, including receipt of CE Mark for our novel xTAG Gastrointestinal Pathogen Panel, the acquisition of EraGen Biosciences, and the expansion of our distribution channel for MAGPIX," added Balthrop. "These accomplishments will help ensure that Luminex delivers high performance solutions to our customers and long term value for our shareholders," Balthrop concluded. REVENUE SUMMARY(in thousands, except percentages)Three Months EndedJune 30,Variance20112010($)(%)(unaudited)System sales

    ,23916%Consumable sales

    18,3979,6988,69990%Royalty revenue

    7,4124,8612,55152%Assay revenue

    9,2617,4391,82224%All other revenue

    4,39643%Six Months EndedJune 30,Variance20112010($)(%)(unaudited)System sales

    2,21915%Consumable sales

    33,39919,51713,88271%Royalty revenue

    14,66810,7103,95837%Assay revenue

    18,84515,0993,74625%All other revenue

    24,41937%Consolidated revenue for the second quarter of 2011 was $47.6 million, a 43% increase over consolidated revenue of $33.2 million for the second quarter of 2010.  GAAP net income for the second quarter of 2011 was $4.6 million, or $0.11 per diluted share, compared with GAAP net income of $0.9 million, or $0.02 per diluted share, for the prior year period. Included in SG&A expenses for the current quarter are approximately $1.3 million of acquisition costs related to the EraGen Biosciences transaction representing an approximate $0.03 per diluted share one time burden.  Exclusive of acquisition costs, the operating activities of EraGen incorporated in our consolidated financial results for the quarter were immaterial.

    Net income for the second quarter of 2011 included non-cash charges of $3.0 million in stock compensation expense associated with ASC 718 and $2.6 million of depreciation and amortization expense.  Net income for the second quarter of 2010 included non-cash charges of $2.4 million in stock compensation expense associated with ASC 718 and $2.1 million of depreciation and amortization expense.  

    LUMINEX CORPORATIONREPORTABLE SEGMENT HIGHLIGHTS(in thousands, except percentages)Three Months EndedJune 30,Variance20112010($)(%)(unaudited)RevenueTechnology and strategic partnerships

    ,98444%Assays and related products

    11,4278,0153,41243%Total Revenue

    47,63833,24214,39643%Operating income (loss)Technology and strategic partnerships

    11,5723,6167,956220%Assays and related products

    (2,775)(1,351)(1,424)-105%Total Operating income

    8,7972,2656,532288%Six Months EndedJune 30,Variance20112010($)(%)(unaudited)RevenueTechnology and strategic partnerships

    7,70335%Assays and related products

    22,76716,0516,71642%Total Revenue

    90,91366,49424,41937%Operating income (loss)Technology and strategic partnerships

    20,2287,91212,316156%Assays and related products

    (3,137)(1,899)(1,238)-65%Total Operating income

    17,0916,01311,078184%FINANCIAL OUTLOOK AND GUIDANCE The Company raises its 2011 annual revenue guidance to a range of $180 million to $185 million from $163 to $170 million.  The updated range of annual revenue is an increase of between 27 to 31 percent over reported 2010 annual revenue and includes an anticipated contribution of $5 to $7 million from EraGen Biosciences.

    CONFERENCE CALL Management will host a conference call to discuss the operating highlights and financial results for the second quarter ended June 30, 2011, on Monday, August 8, 2011, at 4:00 p.m. Central time/ 5:00 p.m. Eastern time.  The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

    Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry.  The Company's xMAP® system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets.  The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.  Further information on Luminex or xMAP can be obtained on the Internet at

    Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding: the expansion of our installed base; expanded distribution for our MAGPIX system; including execution of our distribution relationship with Life Technologies; the development progress of our NeoPlex4 assay product; market acceptance of our RVP FAST and GPP assay products; integration of EraGen Biosciences, Inc.; the ability of our investment in current initiatives and new products to deliver high performance solutions, and drive long-term value for our shareholders; and, projected 2011 revenue. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements.  Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products and technology, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, the uncertainty regarding the outcome or expense of any litigation brought against Luminex, risks relating to Luminex's foreign operations, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies, or selected assets into our consolidated business operations, including the ability to recognize the benefits of our acquisitions, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission.  The forward-looking statements, including the financial guidance and 2011 outlook, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

    LUMINEX CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)June 30,December 31,20112010(unaudited)ASSETSCurrent assets:Cash and cash equivalents

    89,487Restricted cash

    1,0041,002Short-term investments

    29,98328,404Accounts receivable, net

    15,68620,936Inventories, net

    29,32724,932Deferred income taxes

    1,3204,225Prepaids and other

    4,0482,732Total current assets

    136,978171,718Property and equipment, net

    23,66922,084Intangible assets, net

    32,24112,944Deferred income taxes

    8,4926,363Long-term investments



    6,0204,430Total assets

    265,810LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

    7,621Accrued liabilities

    6,4077,444Deferred revenue

    3,6733,866Current portion of long term debt

    466849Total current liabilities

    15,10419,780Long-term debt

    3,1193,351Deferred revenue


    3,6013,511Total liabilities

    25,85830,945Stockholders' equity:Common stock

    4141Additional paid-in capital

    298,676295,422Accumulated other comprehensive gain

    1,4951,150Accumulated deficit

    (52,644)(61,748)Total stockholders' equity

    247,568234,865Total liabilities and stockholders' equity

    265,810LUMINEX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)Three Months EndedSix Months EndedJune 30,June 30,2011201020112010(unaudited)(unaudited)Revenue

    ,494Cost of revenue

    13,81210,08226,35920,558Gross profit

    33,82623,16064,55445,936Operating expenses:Research and development

    7,9456,44115,51511,921Selling, general and administrative

    17,08414,45431,94828,002Total operating expenses

    25,02920,89547,46339,923Income from operations

    8,7972,26517,0916,013Interest expense from long-term debt

    (79)(112)(162)(228)Other income, net

    108114215241Income before income taxes

    8,8262,26717,1446,026Income taxes

    (4,183)(1,383)(8,040)(3,267)Net income

    2,759Net income per share, basic

    .07Shares used in computing net income per share, basic

    41,26241,00141,25140,893Net income per share, diluted

    .07Shares used in computing net income per share, diluted

    42,44642,28142,39841,986The Company has reclassified certain amounts previously classified as a component of selling, general and administrative expenses to research and development expenses to conform to the current period presentation. This reclassification was $0.6 million and $1.1 million for the three and six months ended June 30, 2010, and was not material to the Company's consolidated financial statements.

    LUMINEX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)Three Months EndedSix Months EndedJune 30,June 30,2011201020112010(unaudited)(unaudited)Cash flows from operating activities:Net income

    2,759Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization

    2,6222,1215,1384,284Stock-based compensation

    2,9932,4395,5404,606Deferred income tax benefit

    2,0549113,3792,505Excess income tax benefit from employee stock-based awards


    234(72)305263Changes in operating assets and liabilities:Accounts receivable, net

    68(1,042)6,6565,210Inventories, net

    1,793(547)1,207(2,113)Other assets

    (164)(818)(1,186)(745)Accounts payable

    (1,510)721(4,254)(3,466)Accrued liabilities

    1,9532,038167(1,345)Deferred revenue

    (317)(37)(460)740Net cash provided by operating activities

    12,8685,07421,89111,174Cash flows from investing activities:Purchases of available-for-sale securities

    (22,201)(9,054)(29,247)(21,667)Maturities of available-for-sale securities

    7,25612,99814,17716,193Purchase of property and equipment

    (2,644)(3,985)(3,798)(5,449)Business acquisition consideration, net of cash acquired

    (33,914)(5,036)(33,914)(5,036)Increase in restricted cash

    -(1,000)-(1,000)Purchase of cost method investment

    -(2,000)(2,000)(2,000)Acquired technology rights

    (87)(1,200)(87)(1,200)Net cash used in investing activities

    (51,590)(9,277)(54,869)(20,159)Cash flows from financing activities:Payments on debt

    (885)(895)(885)(895)Proceeds from issuance of common stock

    5903018181,440Payments for stock repurchases

    (1,436)-(4,686)-Excess income tax benefit from employee stock-based awards

    1,5011,5243,7051,524Net cash (used in) provided by financing activities

    (230)930(1,048)2,069Effect of foreign currency exchange rate on cash

    18614959Change in cash and cash equivalents

    (38,951)(3,187)(33,877)(6,857)Cash and cash equivalents, beginning of period

    94,56187,17389,48790,843Cash and cash equivalents, end of period


    Harriss T. Currie

    Matthew ScaloVice President, Finance and Chief Financial Officer

    Sr. Director of Investor Relations512-219-8020

    SOURCE Luminex Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Luminex Corporation Receives U.S. FDA Clearance for New, Front Line Respiratory Viral Panel Test
    2. Luminex Corporation Second Quarter Earnings Release Scheduled for August 8, 2011
    3. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
    4. Luminex Corporation Named Most Innovative Company of the Year and Receives Business Innovation of the Year Award for MAGPIX® System
    5. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
    6. Luminex and Life Technologies Sign Agreement for Global Distribution of the Award-Winning MAGPIX® Multiplexing Instrument
    7. Luminex Corporation to Present at Jefferies 2011 Global Healthcare Conference
    8. Luminex Corporation Reports First Quarter 2011 Results
    9. Luminex Corporation First Quarter Earnings Release Scheduled for May 9, 2011
    10. Luminex Corporation Wins Prestigious Medical Design Excellence Award
    11. Luminex Corporation to Present at Cowen and Companys 31st Annual Health Care Conference
    Post Your Comments:
    (Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
    (Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
    (Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
    (Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
    (Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
    (Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
    (Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
    Breaking Medicine News(10 mins):